Press Release Archive

Innovation June 12, 2021

New Phase 3 Study Results Show IMBRUVICA^® (ibrutinib)-Based Combination Regimen as an All-Oral Fixed-Duration Treatment Demonstrated Superior Progression-Free Survival in Adult Patients with Previously Untreated Chronic Lymphocytic Leukemia

New Phase 3 Study Results Show IMBRUVICA^® (ibrutinib)-Based Combination Regimen as an All-Oral Fixed-Duration Treatment Demonstrated Superior Progression-Free Survival in Adult Patients with Previously Untreated Chronic Lymphocytic Leukemia

GLOW study presented as a late-breaking abstract at the European Hematology Association (EHA) Virtual Congress

Innovation June 12, 2021

Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX^®(daratumumab) in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant Ineligible

Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX^®(daratumumab) in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant Ineligible

After nearly five years of follow-up, median progression-free survival was not reached, and a significant overall survival benefit was observed; data will be presented as a late-breaking abstract at the European Hematology Association (EHA) Virtual Congress

Our Company June 11, 2021

Johnson & Johnson Statement on Supply of its Single-shot COVID-19 Vaccine

Johnson & Johnson Statement on Supply of its Single-shot COVID-19 Vaccine

Our Company June 11, 2021

Johnson & Johnson Announces Six Global Winners for the 2021 Women in STEM²D Scholar Awards

Johnson & Johnson Announces Six Global Winners for the 2021 Women in STEM²D Scholar Awards

Garnering more than 650 applications from 40 countries, the Company recognizes female researchers for their groundbreaking work in Science, Technology, Engineering, Math, Manufacturing and Design (STEM²D).

Each recipient will receive $150,000 in funding and three years of mentorship from Johnson & Johnson to investigate optimizing cancer immunotherapy, reducing health and climate impacts of plastic, promoting off-grid production of fresh water, advancing urogynecological health, and improving hand function through assistive technologies.

Our Company June 10, 2021

Johnson & Johnson Statement on FDA Approval of Shelf Life Extension for Company’s COVID-19 Vaccine

Johnson & Johnson Statement on FDA Approval of Shelf Life Extension for Company’s COVID-19 Vaccine

Our Company June 09, 2021

Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

Our Company June 09, 2021

Johnson & Johnson Releases 2020 Health for Humanity Report Highlighting Performance and Progress on Environmental, Social and Governance Priorities

Johnson & Johnson Releases 2020 Health for Humanity Report Highlighting Performance and Progress on Environmental, Social and Governance Priorities

Our Company June 04, 2021

Statement on the SAGE Recommendation Regarding the Johnson & Johnson Ebola Vaccine Regimen

Statement on the SAGE Recommendation Regarding the Johnson & Johnson Ebola Vaccine Regimen

Innovation June 02, 2021

New Phase 3b Psoriatic Arthritis (PsA) Data Show First-in-Class TREMFYA^® (guselkumab) Achieved Robust Joint Symptom Improvement and Complete Skin Clearance in Patients with Inadequate Response to Tumor Necrosis Factor Inhibition (TNFi-IR)

New Phase 3b Psoriatic Arthritis (PsA) Data Show First-in-Class TREMFYA^® (guselkumab) Achieved Robust Joint Symptom Improvement and Complete Skin Clearance in Patients with Inadequate Response to Tumor Necrosis Factor Inhibition (TNFi-IR)

57.7 percent achieved ≥20 percent improvement in joint symptoms (ACR20) and 53.4 percent achieved complete skin clearance (PASI 100) at one year in COSMOS, the first study of a selective interleukin (IL)-23 inhibitor in a true TNFi-IR patient population

Of 34 Janssen abstracts at the European League Against Rheumatism (EULAR) E-Congress, many present efficacy and safety data for TREMFYA in treating adults with active PsA

Innovation June 01, 2021

Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Deep, Diverse Pipeline and Portfolio at ASCO and EHA Virtual Scientific Programs

Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Deep, Diverse Pipeline and Portfolio at ASCO and EHA Virtual Scientific Programs

- Clinical Data from More Than 10 Approved and Investigational Treatments for Solid Tumors and Hematologic Malignancies to be Presented During the 2021 ASCO Annual Meeting
- Multiple Myeloma and Chronic Lymphocytic Leukemia Data to be Featured During EHA 2021 Virtual Congress

Internet Explorer is no longer supported by this website.